Betty Kwati

About

The HIV pandemic has since the 1980’s been responsibly for 35 million deaths across the globe. South Africa bears a particularly heave burden when it comes to the disease with 5.7 million cases as of 2017. A key local issue is the need for affordable anti-retroviral’s for the management of the disease, unfortunately, a lack of local manufacturing has meant that afflicted South Africans often suffer with demand often outweighing supply. Betty’s masters research involved process development towards the anti-HIV drugs tenofovir diisoproxil and tenofovir alenfanamide where she aimed to develop more economical routes to these critical pharmaceuticals utilising both traditional batch and flow techniques.

Dissertation

Investigating a semi-continuous synthetic pathway for the preparation of the antiretroviral drugs tenofovir disoproxil and tenofovir alafenamide

Conferences

  1. 2016 Frank Warren Conference, Rhodes, South Africa, December 2016: A semi-continuous flow synthesis of anti-retroviral drug, Tenofovir Alafenamide Fumarate (TAF), B. Kwati*, D.L. Riley